Trillium Therapeutics Inc (TRIL)

[NY1972]

Notes

As of June 30, 2016, Trillium had cash of $60.1 million.
Net loss for the six months ended June 30, 2016 of $14.8 million

TTI-621, a potent SIRPaFc (IgG1) fusion protein targeting CD47, continues on schedule with a clinical update expected by the end of 2016.

Phase 1 trial with TTI-621 in patients with select solid tumors

Canadian sites to be included in Phase 1b expansion cohorts.